Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.

A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.

On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.